AMSTERDAM, August 29 /PRNewswire-FirstCall/ -- Amsterdam Molecular
Therapeutics (Euronext: AMT), a leader in the field of human gene therapy,
today reported its results for the first half year of 2007.

Highlights

- Successful IPO, raising gross proceeds of EUR 55.7 million

- Cash & cash equivalents of EUR 56.3 million at June 30, 2007

- Exclusive license to all gene therapy products from CIMA, one of
Europe's leading gene therapy centers

Total revenues for the six months ended June 30, 2007, were EUR 50,000
compared to EUR 208,000 for the same period in 2006. The decrease was
primarily due to a decrease of government grants, since the grant project
for LPL deficiency was completed in 2006.

The operating loss increased to EUR 7.2 million for the six months
ended June 30, 2007, from EUR 4.2 million for the same period in 2006. This
was primarily due to the increase of research & development costs to EUR
3.8 million for the six months ended June 30, 2007 from EUR 1.9 million in
the same period of 2006. This increase is particularly related to the
development work on the company's lead product AMT 011 for LPL deficiency
and increased staffing. General and administrative costs rose primarily as
a function of the higher number of staff employed, stock based
compensation, increased facility expenses and advisory costs. These costs
increased to EUR 3.5 million for the six months ended June 30, 2007, from
EUR 2.6 million for the same period in 2006.

(Date:7/30/2015)... July 30, 2015 With over 60,000 customers across the globe, ISN improves the ... hiring organizations with more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 ... Headquartered in Dallas, TX , ...

(Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as a follow ... service business units, Whitehouse Laboratories is pleased to announce that it has begun construction ... Center of Excellence and will be strictly dedicated to basic USP 51, USP 61, and ...

(Date:7/29/2015)... , July 30, 2015 According ... Market - Growth, Trends & Forecasts (2015-2020), , published by ... US$ 30.25 billion by the end of 2020, with ... accounting for more than 40% of the global market size. ... at a CAGR of 13.7% during the period of (2015-2020). ...

... Inc.,(Nasdaq: ONTY ) (TSX:ONY), a biotechnology company ... the treatment of cancer,today announced that Robert Kirkman, ... present at two upcoming investment conferences., The ... the Invest,Northwest CEO and Investor Forum at 4:10 ...

... Inc. (Nasdaq: ALXA ) announced today that it ... 2007, on Monday, March 17,2008, following the close of ... conference call to discuss the financial results and other,clinical ... day. A,replay of the call will be available for ...

(Date:7/21/2015)... , July 21, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...

... far the shrimp fisherman Uwe Abken has had little interest ... from the East Friesian town of Neuharlingersiel has been taking ... been recording which North Sea exotics and rare migratory fish ... Wtjen from the German Alfred Wegener Institute for Polar and ...

... actively pump a wealth of molecules across the membrane. ... humans. Genetic defects in ABC transporters can trigger metabolic ... and certain ABC transporters also cause resistance to a ... of ABC transporters that pump chemotherapeutic substances out of ...

... series of refrigerated cold traps offers a ... low volatility/aqueous solvents or high volatility solvents. ... vacuum concentrators/centrifugal evaporators. Also used for maintaining ... as used in electron microscopes. Can be ...

... Trap is specifically designed for efficient ... as DMSO and DMF in the ... refrigeration system set at -5 o ... DMSO, while completely eliminating the risk ...